The approval of the first oncolytic viral therapy, Imlygic, in the United States and EU5 in 2015 and 2016, respectively, marks a significant milestone for cancer vaccines and viral therapies, making these therapies exciting to watch. Cancer Vaccines and Viral Therapies provides comprehensive multi-indication coverage of currently available cancer vaccines (Provenge in the United States and Imlygic in the United States and EU5) and analysis of their ongoing clinical development across the oncology indications. In addition, analysis of late-phase emerging therapies and their future positioning in oncology is provided based on insights from interviewed thought leaders and analysis of secondary market research sources. This analysis uniquely enables a comparison of the potential of the therapies in this drug class across a breath of indications in addition to determining their total peak-year sales across oncology indications.

Table of contents

  • Therapeutic Vaccines And Viral Therapy - Landscape & Forecast - Special Topic Report
    • Market Outlook
      • Introduction
        • Key Findings
        • Expert Insight
        • Market Overview
        • Major-Market Share of Cancer Vaccines and Viral Therapies by Subclass: 2015
        • Major-Market Share of Cancer Vaccines and Viral Therapies by Subclass: 2025
        • Major-Market Share of Cancer Vaccines and Viral Therapies by Region: 2015
        • Major-Market Share of Cancer Vaccines and Viral Therapies by Region: 2025
        • Major-Market Share of Cancer Vaccines and Viral Therapies by Indication: 2015
        • Major-Market Share of Cancer Vaccines and Viral Therapies by Indication: 2025
        • Major-Market Sales of Cancer Vaccines and Viral Therapies Across All Indications: 2015-2025
      • Market Drivers and Constraints
        • What Factors Are Driving the Cancer Vaccines and Viral Therapies Market?
        • What Factors Are Constraining the Cancer Vaccines and Viral Therapies Market?
      • Talimogene Laherparepvec
        • Sipuleucel-T
          • Rilimogene Galvacirepvec
            • DCVax-L
              • ICT-107
                • Sales of Cancer Vaccines and Viral Therapies
                • Epidemiology
                  • Introduction
                    • Key Findings
                    • Overview
                  • Epidemiology Populations
                    • Disease Definition
                    • Methods
                    • Sources Used for Newly Diagnosed Incidence of Prostate Cancer
                    • Number of Newly Diagnosed Incident Cases of Prostate Cancer in the Major Pharmaceutical Markets, 2015-2025 (thousands)
                    • Disease Definition
                    • Methods
                    • Sources Used for Newly Diagnosed Incidence of Malignant Melanoma
                    • Number of Newly Diagnosed Incident Cases of Malignant Melanoma in the Major Pharmaceutical Markets, 2015-2025 (hundreds)
                    • Disease Definition
                    • Methods
                    • Sources Used for Newly Diagnosed Incidence of Glioma
                    • Number of Diagnosed Incident Cases of Glioma by Histology in the Major Markets, 2015-2025
                    • Definition
                    • Methods
                    • Sources Used for Recurrent Incidence of Prostate Cancer
                    • Number of Biochemically and Metastatic Recurrent Incident Cases of Prostate Cancer in the Major Pharmaceutical Markets, 2015-2025
                    • Disease Definition
                    • Methods
                    • Sources for Malignant Melanoma Recurrent Incidence
                    • Recurrent Incident Cases of Malignant Melanoma in the Major Pharmaceutical Markets, 2015-2025
                    • Definition
                    • Methods
                    • Sources Used for Transformed Incidence of Anaplastic Glioma
                    • Transformed Incident Cases of Anaplastic Glioma, 2015-2025
                    • Sources for Prostate Cancer Drug-Treatable Population
                    • Number of Drug Treatable Cases of First-Line Metastatic Castrate-Resistant Prostate Cancer in the Major Pharmaceutical Markets, 2015-2025
                    • Sources Used for Drug-Treatable Cases of Malignant Melanoma, 2015-2015
                    • Drug-Treatable Cases of Malignant Melanoma, 2015-2025
                    • Sources Used for Drug-Treatable Populations of Glioma
                    • Drug-Treatable Cases of Grade 4 Glioma (Glioblastoma)
                • Current Therapies
                  • Introduction
                    • Key Findings
                    • Expert Insight
                  • Current Therapies Overview
                    • Marketer, Indication, and Approval Year for Current Cancer Vaccines and Viral Therapies
                  • Clinical Trial End Points
                    • Key End Points Used in Clinical Trials Evaluating Cancer Vaccines and Viral Therapies
                    • Immune-Response Criteria
                    • Expert Insight: Clinical Trial End Points Used in Clinical Trials of Cancer Vaccines and Viral Therapies
                    • Expert Insight: Clinical End Points Used in Trial Evaluating Therapeutic Cancer Vaccines and Viral Therapies
                    • Expert Insight: Key Clinical Trial Design Challenges in Evaluating Cancer Vaccines and Viral Therapies
                    • Expert Insight: Clinical Trial Design of Trials Examining Currently Approved Vaccines and Viral Therapies
                  • Provenge
                    • Current Use of Provenge
                    • Key Results from Select Clinical Trials Investigating Provenge in Prostate Cancer
                    • Ongoing Clinical Development of Provenge
                    • Expert Insight: Use of Provenge in the Treatment of Prostate Cancer
                    • Expert Insight: Provenge in Prostate Cancer
                  • Imlygic
                    • Current Use of Imlygic
                    • Key Results from Select Clinical Trials Investigating Imlygic in Malignant Melanoma
                    • Ongoing Clinical Development of Imlygic
                    • Ongoing Select Clinical Trials Investigating Imlygic
                    • Expert Insight: Use of Imlygic in the Treatment of Malignant Melanoma
                    • Expert Insight: Imlygic in Malignant Melanoma
                • Emerging Therapies
                  • Introduction
                    • Key Findings
                    • Expert Insight
                    • Pipeline Overview
                    • Cancer Vaccines and Viral Therapies Pipeline Trends
                  • Late-Phase Pipeline Analysis
                    • Notable Developments in the Late-Phase Pipeline of Cancer Vaccines and Viral Therapies
                    • Cancer Vaccines and Viral Therapies in Late-Phase Development
                    • Estimated Market Authorization Dates of Key Emerging Cancer Therapeutic Vaccines and Viral Therapies
                    • Emerging Cancer Vaccines and Viral Therapies with Sales Potential: Population Positioning
                  • Key Emerging Therapies
                    • Phase III Trials Investigating Dendritic-Cell Vaccines
                    • DCVax-L Profile
                    • DCVax-L Clinical Development
                    • Expert Insight: Use of DCVax-L in the Treatment of Glioblastoma
                    • Expert Insight: DCVax-L
                    • Expectations for Launch and Sales Opportunity of DCVax-L in Glioblastoma
                    • ICT-107 Profile
                    • ICT-107 Clinical Development
                    • Expert Insight: Use of ICT-107 in the Treatment of Glioblastoma
                    • Expert Insight: ICT-107
                    • Expectations for Launch and Sales Opportunity of ICT-107 in Glioblastoma
                    • AGS-003 Profile
                    • AGS-003 Clinical Development
                    • Expert Insight: Use of AGS-003 in the Treatment of Renal Cell Carcinoma
                    • Expert Insight: AGS-003
                    • Expectations for Launch and Sales Opportunity of AGS-003 in Renal Cell Carcinoma
                    • Stapuldencel-T Profile
                    • Stapuldencel-T Clinical Development
                    • Expert Insight: Use of Stapuldencel-T in the Treatment of Prostate Cancer
                    • Expert Insight: Stapuldencel-T
                    • Expectations for Launch and Sales Opportunity of Stapuldencel-T in Prostate Cancer
                    • Phase III Trials Investigating Antigen- and Peptide-Based Vaccines
                    • BV-NSCLC-002 Profile
                    • BV-NSCLC-002 Clinical Development
                    • Expert Insight: Use of BV-NSCLC-002 in the Treatment of NSCLC
                    • Expert Insight: BV-NSCLC-002
                    • Expectations for Launch and Sales Opportunity of BV-NSCLC-002 in NSCLC
                    • OSE-2101 Profile
                    • OSE-2101 Clinical Development
                    • Expert Insight: Use of OSE-2101 in the Treatment of NSCLC
                    • Expert Insight: OSE-2101
                    • Expectations for Launch and Sales Opportunity of OSE-2101 in NSCLC
                    • Seviprotimut-L Profile
                    • Seviprotimut-L Clinical Development
                    • Expert Insight: Use of Seviprotimut-L in the Treatment of Malignant Melanoma
                    • Expert Insight: Seviprotimut-L
                    • Expectations for Launch and Sales Opportunity of Seviprotimut-L in Malignant Melanoma
                    • ITK-1 Profile
                    • ITK-1 Clinical Development
                    • Expert Insight: Use of ITK-1 in the Treatment of Prostate Cancer and Glioblastoma
                    • Expert Insight: ITK-1
                    • Expectations for Launch and Sales Opportunity of ITK-1 in Prostate Cancer and Glioblastoma
                    • Axalimogene Filolisbac Profile
                    • Axalimogene Filolisbac Clinical Development
                    • Expert Insight: Use of Axalimogene Filolisbac in the Treatment of Cervical Cancer
                    • Expectations for Launch and Sales Opportunity of Axalimogene Filolisbac in Cervical Cancer
                    • Phase II/III and Phase III Trials Investigating Tumor-Cell Vaccines
                    • OncoVAX Profile
                    • OncoVAX Clinical Development
                    • Expert Insight: Use of OncoVAX in the Treatment of Colorectal Cancer
                    • Expert Insight: OncoVAX
                    • Expectations for Launch and Sales Opportunity of OncoVAX in Colorectal Cancer
                    • M-Vax Profile
                    • M-Vax Clinical Development
                    • Expert Insight: Use of M-Vax in the Treatment of Malignant Melanoma
                    • Expert Insight: M-Vax
                    • Expectations for Launch and Sales Opportunity of M-Vax in Malignant Melanoma
                    • Gemogenovatucel-T Profile
                    • Gemogenovatucel-T Clinical Development
                    • Expert Insight: Use of Gemogenovatucel-T in the Treatment of Ovarian Cancer
                    • Expert Insight: Gemogenovatucel-T
                    • Expectations for Launch and Sales Opportunity of Gemogenovatucel-T in Ovarian Cancer
                    • Phase II/III and Phase III Trials Investigating Viral-Vector Immunotherapies
                    • Rilimogene Galvacirepvec Profile
                    • Rilimogene Galvacirepvec Clinical Development
                    • Expert Insight: Use of Rilimogene Galvacirepvec in the Treatment of Prostate Cancer
                    • Expert Insight: Rilimogene Galvacirepvec
                    • Expectations for Launch and Sales Opportunity of Rilimogene Galvacirepvec in Prostate Cancer
                    • Aglatimagene Besadenovec (Plus Valacyclovir) Profile
                    • Aglatimagene Besadenovec (Plus Valacyclovir) Clinical Development
                    • Expert Insight: Use of Aglatimagene Besadenovec (Plus Valacyclovir) in the Treatment of Prostate Cancer
                    • Expert Insight: Aglatimagene Besadenovec (Plus Valacyclovir)
                    • Expectations for Launch and Sales Opportunity of Aglatimagene Besadenovec (Plus Valacyclovir) in Prostate Cancer
                    • TG-4010 Profile
                    • TG-4010 Clinical Development
                    • Expert Insight: Use of TG-4010 in the Treatment of NSCLC
                    • Expert Insight: TG-4010
                    • Expectations for Launch and Sales Opportunity of TG-4010 in NSCLC
                    • Ofranergene Obadenovec Profile
                    • Ofranergene Obadenovec Clinical Development
                    • Expert Insight: Use of Ofranergene Obadenovec in the Treatment of Glioblastoma
                    • Expert Insight: Ofranergene Obadenovec
                    • Expectations for Launch and Sales Opportunity of Ofranergene Obadenovec in Glioblastoma
                    • Vocimagene Amiretrorepvec (Plus 5-FC) Profile
                    • Vocimagene Amiretrorepvec (Plus 5-FC) Clinical Development
                    • Expert Insight: Use of Vocimagene Amiretrorepvec (Plus 5-FC) in the Treatment of High-Grade Glioma
                    • Expert Insight: Vocimagene Amiretrorepvec (Plus 5-FC)
                    • Expectations for Launch and Sales Opportunity of Vocimagene Amiretrorepvec in High-Grade Glioma
                    • Phase III Trials Investigating Oncolytic Viral Therapies
                    • CG-0070 Profile
                    • CG-0070 Clinical Development
                    • Expert Insight: Use of CG-0070 in the Treatment of Bladder Cancer
                    • Expert Insight: CG-0070
                    • Expectations for Launch and Sales Opportunity of CG-0070 in Bladder Cancer
                    • Pelareorep Profile
                    • Pelareorep Clinical Development
                    • Expert Insight: Use of Pelareorep in the Treatment of SCCHN
                    • Expert Insight: Pelareorep
                    • Expectations for Launch and Sales Opportunity of Pelareorep in SCCHN
                    • Pexastimogene Devacirepvec Profile
                    • Pexastimogene Devacirepvec Clinical Development
                    • Expert Insight: Use of Pexastimogene Devacirepvec in the Treatment of Hepatocellular Carcinoma
                    • Expert Insight: Pexastimogene Devacirepvec
                    • Expectations for Launch and Sales Opportunity of Pexastimogene Devacirepvec in Hepatocellular Carcinoma
                  • Early-Phase Pipeline Analysis
                    • Notable Developments in the Early-Phase Pipeline of Cancer Vaccines and Viral Therapies
                    • Select Cancer Vaccines and Viral Therapies in Early-Phase Development
                • Methodology
                  • Bottom-Up Forecasting Overview
                  • Patient Populations
                  • General Sources of Data
                  • Emerging Therapy Prices
                • Appendix
                  • Key Abbreviations Related to Cancer Vaccines and Viral Therapies in Oncology
                  • Experts Interviewed
                  • Bibliography

              Author(s): Karen Pomeranz, PhD

              Karen Pomeranz is a senior business insights analyst analyst in the oncology team at Decision Resources Group. She has worked on a breadth of indications including glioma, hepatocellular carcinoma, gastrointestinal stromal tumor, malignant melanoma, renal cell carcinoma, breast cancer, and colorectal cancer. She has worked on several products lines as well as with the Decision Resources Group consulting team on many projects.

              Her previous work experience includes conducting scientific research at Imperial College, London and Tel-Aviv University. Dr. Pomeranz holds an M.Sc. from Tel-Aviv University and a Ph.D. from Imperial College, London.